Fungal sphingolipids: role in the regulation of virulence and potential as targets for future antifungal therapies

References

• Brown GD, Denning DW, Levitz SM. Tackling human fungal infections. American Association for the Advancement of Science; 2012.
   Google Scholar
• Brown GD, Denning DW, Gow NA, et al. Hidden killers: human fungal infections. Sci Transl Med. 2012;4(165):165rv13–165rv13.
   PubMed Web of Science ®Google Scholar
• Rodrigues ML. The multifunctional fungal ergosterol. MBio. 2018;9(5):e01755–18.
   PubMed Web of Science ®Google Scholar
• Gallis HA, Drew RH, Pickard WW, et al. 30 years of clinical experience. Rev Infect Dis. 1990;12(2):308–329.
   PubMedGoogle Scholar
• Gray KC, Palacios DS, Dailey I, et al. Amphotericin primarily kills yeast by simply binding ergosterol. Proc Nat Acad Sci. 2012;109(7):2234–2239.
   PubMed Web of Science ®Google Scholar
• Anderson TM, Clay MC, Cioffi AG, et al. Amphotericin forms an extramembranous and fungicidal sterol sponge. Nat Chem Biol. 2014;10(5):400.
   PubMed Web of Science ®Google Scholar
• Allen D, Wilson D, Drew R, et al. Azole antifungals: 35 years of invasive fungal infection management. Expert Rev Anti Infect Ther. 2015;13(6):787–798.
   PubMed Web of Science ®Google Scholar
• Kathiravan MK, Salake AB, Chothe AS, et al. The biology and chemistry of antifungal agents: a review. Bioorg Med Chem. 2012;20(19):5678–5698.
   PubMed Web of Science ®Google Scholar
• Veen M, Stahl U, Lang C. Combined overexpression of genes of the ergosterol biosynthetic pathway leads to accumulation of sterols in Saccharomyces cerevisiae. FEMS Yeast Res. 2003;4(1):87–95.
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Esquivel BD, White TC. Overexpression or deletion of ergosterol biosynthesis genes alters doubling time, response to stress agents, and drug susceptibility in Saccharomyces cerevisiae. MBio. 2018;9(4):e01291–18.
   PubMed Web of Science ®Google Scholar
• Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev. 1999;12(1):40–79.
   PubMed Web of Science ®Google Scholar
• Kelly S, Lamb D, Kelly D, et al. Resistance to fluconazole and cross‐resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol Δ5, 6‐desaturation. FEBS Lett. 1997;400(1):80–82.
   PubMed Web of Science ®Google Scholar
• Perfect JR. The antifungal pipeline: a reality check. Nat Rev Drug Discov. 2017;16(9):603.
   PubMed Web of Science ®Google Scholar
• Gow NA, Latge J-P, Munro CA The fungal cell wall: structure, biosynthesis, and function. The fungal kingdom; 2017. p. 267–292.
   Google Scholar
• Denning DW. Echinocandin antifungal drugs. Lancet. 2003;362(9390):1142–1151.
   PubMed Web of Science ®Google Scholar
• Chen SC-A, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections. Drugs. 2011;71(1):11–41.
   PubMed Web of Science ®Google Scholar
• Cowen LE. The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype. Nature Rev Microbiol. 2008;6(3):187–198.
   PubMed Web of Science ®Google Scholar
• Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis. 2002;2(2):73–85.
   PubMed Web of Science ®Google Scholar
• Coste A, Selmecki A, Forche A, et al. Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot Cell. 2007;6(10):1889–1904.
   PubMedGoogle Scholar
• da Silva Ferreira ME, Capellaro JL, Dos Reis Marques E, et al. In vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance. Antimicrob Agents Chemother. 2004;48(11):4405–4413.
   PubMed Web of Science ®Google Scholar
• Nascimento AM, Goldman GH, Park S, et al. Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole. Antimicrob Agents Chemother. 2003;47(5):1719–1726.
   PubMed Web of Science ®Google Scholar
• Flowers SA, Colón B, Whaley SG, et al. Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans. Antimicrob Agents Chemother. 2015;59(1):450–460.
   PubMed Web of Science ®Google Scholar
• Xiang M-J, Liu J-Y, Ni P-H, et al. Erg11 mutations associated with azole resistance in clinical isolates of Candida albicans. FEMS Yeast Res. 2013;13(4):386–393.
   PubMed Web of Science ®Google Scholar
• Rodero L, Mellado E, Rodriguez AC, et al. G484S amino acid substitution in lanosterol 14-α demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate. Antimicrob Agents Chemother. 2003;47(11):3653–3656.
   PubMed Web of Science ®Google Scholar
• Flowers SA, Barker KS, Berkow EL, et al. Gain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans. Eukaryot Cell. 2012;11(10):1289–1299.
   PubMedGoogle Scholar
• Selmecki A, Forche A, Berman J. Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science. 2006;313(5785):367–370.
   PubMed Web of Science ®Google Scholar
• Selmecki A, Gerami‐Nejad M, Paulson C, et al. An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1. Mol Microbiol. 2008;68(3):624–641.
   PubMed Web of Science ®Google Scholar
• Chowdhary A, Sharma C, Hagen F, et al. Exploring azole antifungal drug resistance in Aspergillus fumigatus with special reference to resistance mechanisms. Future Microbiol. 2014;9(5):697–711.
   PubMed Web of Science ®Google Scholar
• Park S, Kelly R, Kahn JN, et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother. 2005;49(8):3264–3273.
   PubMed Web of Science ®Google Scholar
• Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat. 2007;10(3):121–130.
   PubMed Web of Science ®Google Scholar
• Dickson RC, Lester RL. Sphingolipid functions in Saccharomyces cerevisiae. Biochim Biophys Acta (BBA)-Mol Cell Biol Lipids. 2002;1583(1):13–25.
   PubMed Web of Science ®Google Scholar
• Ren J, Hannun Y. Metabolism and roles of sphingolipids in yeast Saccharomyces cerevisiae. Cham, Switzerland: Springer International Publishing; 2017. p. 1–21.
   Google Scholar
• Martin SW, Konopka JB. Lipid raft polarization contributes to hyphal growth in Candida albicans. Eukaryot Cell. 2004;3(3):675–684.
   PubMedGoogle Scholar
• Nichols CB, Fraser JA, Heitman J. PAK kinases Ste20 and Pak1 govern cell polarity at different stages of mating in Cryptococcus neoformans. Mol Biol Cell. 2004;15(10):4476–4489.
   PubMed Web of Science ®Google Scholar
• Pearson CL, Xu K, Sharpless KE, et al. MesA, a novel fungal protein required for the stabilization of polarity axes in Aspergillus nidulans. Mol Biol Cell. 2004;15(8):3658–3672.
   PubMed Web of Science ®Google Scholar
• Takeshita N, Higashitsuji Y, Konzack S, et al. Apical sterol-rich membranes are essential for localizing cell end markers that determine growth directionality in the filamentous fungus Aspergillus nidulans. Mol Biol Cell. 2008;19(1):339–351.
   PubMed Web of Science ®Google Scholar
• Farnoud AM, Toledo AM, Konopka JB, et al. Raft-like membrane domains in pathogenic microorganisms. In: Current topics in membranes. Vol. 75. Elsevier; 2015. p. 233–268.
   Google Scholar
• Rodrigues ML, Travassos LR, Miranda KR, et al. Human antibodies against a purified glucosylceramide from Cryptococcus neoformans inhibit cell budding and fungal growth. Infect Immun. 2000;68(12):7049–7060.
   PubMed Web of Science ®Google Scholar
• Rodrigues ML, Nimrichter L, Oliveira DL, et al. Vesicular polysaccharide export in Cryptococcus neoformans is a eukaryotic solution to the problem of fungal trans-cell wall transport. Eukaryot Cell. 2007;6(1):48–59.
   PubMedGoogle Scholar
• Oliveira DL, Freire-de-Lima CG, Nosanchuk JD, et al. Extracellular vesicles from Cryptococcus neoformans modulate macrophage functions. Infect Immun. 2010;78(4):1601–1609.
   PubMed Web of Science ®Google Scholar
• Vargas G, Rocha JD, Oliveira DL, et al. Compositional and immunobiological analyses of extracellular vesicles released by C andida albicans. Cell Microbiol. 2015;17(3):389–407.
   PubMed Web of Science ®Google Scholar
• Singh A, Del Poeta M. Lipid signalling in pathogenic fungi. Cell Microbiol. 2011;13(2):177–185.
   PubMed Web of Science ®Google Scholar
• Dickson RC. Thematic review series: sphingolipids. New insights into sphingolipid metabolism and function in budding yeast. J Lipid Res. 2008;49(5):909–921.
   PubMed Web of Science ®Google Scholar
• Nagiec MM, Baltisberger JA, Wells GB, et al. The LCB2 gene of Saccharomyces and the related LCB1 gene encode subunits of serine palmitoyltransferase, the initial enzyme in sphingolipid synthesis. Proc Nat Acad Sci. 1994;91(17):7899–7902.
   PubMed Web of Science ®Google Scholar
• Buede R, Rinker-Schaffer C, Pinto W, et al. Cloning and characterization of LCB1, a Saccharomyces gene required for biosynthesis of the long-chain base component of sphingolipids. J Bacteriol. 1991;173(14):4325–4332.
   PubMed Web of Science ®Google Scholar
• Cheng J, Park T-S, Fischl AS, et al. Cell cycle progression and cell polarity require sphingolipid biosynthesis in Aspergillus nidulans. Mol Cell Biol. 2001;21(18):6198–6209.
   PubMed Web of Science ®Google Scholar
• Miyake Y, Kozutsumi Y, Nakamura S, et al. Serine palmitoyltransferase is the primary target of a sphingosine-like immunosuppressant, ISP-1/myriocin. Biochem Biophys Res Commun. 1995;211(2):396–403.
   PubMed Web of Science ®Google Scholar
• Wadsworth JM, Clarke DJ, McMahon SA, et al. The chemical basis of serine palmitoyltransferase inhibition by myriocin. J Am Chem Soc. 2013;135(38):14276–14285.
   PubMed Web of Science ®Google Scholar
• Hanada K, Nishijima M, Fujita T, et al. Specificity of inhibitors of serine palmitoyltransferase (SPT), a key enzyme in sphingolipid biosynthesis, in intact cells: a novel evaluation system using an SPT-defective mammalian cell mutant. Biochem Pharmacol. 2000;59(10):1211–1216.
   PubMed Web of Science ®Google Scholar
• He Q, Johnson VJ, Osuchowski MF, et al. Inhibition of serine palmitoyltransferase by myriocin, a natural mycotoxin, causes induction of c-myc in mouse liver. Mycopathologia. 2004;157(3):339–347.
   PubMed Web of Science ®Google Scholar
• de Melo NR, Abdrahman A, Greig C, et al. Myriocin significantly increases the mortality of a non-mammalian model host during Candida pathogenesis. PLoS One. 2013;8:11.
   Web of Science ®Google Scholar
• Spitzer M, Griffiths E, Blakely KM, et al. Cross‐species discovery of syncretic drug combinations that potentiate the antifungal fluconazole. Mol Syst Biol. 2011;7(1):499.
   PubMedGoogle Scholar
• Fornarotto M, Xiao L, Hou Y, et al. Sphingolipid biosynthesis in pathogenic fungi: identification and characterization of the 3-ketosphinganine reductase activity of Candida albicans and Aspergillus fumigatus. Biochim Biophys Acta (BBA)-Mol Cell Biol Lipids. 2006;1761(1):52–63.
   PubMed Web of Science ®Google Scholar
• Gow NA, Brown AJ, Odds FC. Fungal morphogenesis and host invasion. Curr Opin Microbiol. 2002;5(4):366–371.
   PubMed Web of Science ®Google Scholar
• Warnecke D, Heinz E. Recently discovered functions of glucosylceramides in plants and fungi. Cell Mol Life Sci. 2003;60(5):919–941.
   PubMed Web of Science ®Google Scholar
• Kihara A, Igarashi Y. FVT-1 is a mammalian 3-ketodihydrosphingosine reductase with an active site that faces the cytosolic side of the endoplasmic reticulum membrane. J Biol Chem. 2004;279(47):49243–49250.
   PubMed Web of Science ®Google Scholar
• Gupta SD, Gable K, Han G, et al. Tsc10p and FVT1: topologically distinct short-chain reductases required for long-chain base synthesis in yeast and mammals. J Lipid Res. 2009;50(8):1630–1640.
   PubMed Web of Science ®Google Scholar
• Barreto-Bergter E, Pinto MR, Rodrigues ML. Structure and biological functions of fungal cerebrosides. Anais da Academia Brasileira de Ciências. 2004;76(1):67–84.
   PubMed Web of Science ®Google Scholar
• Li S, Du L, Yuen G, et al. Distinct ceramide synthases regulate polarized growth in the filamentous fungus Aspergillus nidulans. Mol Biol Cell. 2006;17(3):1218–1227.
   PubMed Web of Science ®Google Scholar
• Ternes P, Wobbe T, Schwarz M, et al. Two pathways of sphingolipid biosynthesis are separated in the yeast Pichia pastoris. J Biol Chem. 2011;286(13):11401–11414.
   PubMed Web of Science ®Google Scholar
• Cheon SA, Bal J, Song Y, et al. Distinct roles of two ceramide synthases, CaLag1p and CaLac1p, in the morphogenesis of Candida albicans. Mol Microbiol. 2012;83(4):728–745.
   PubMed Web of Science ®Google Scholar
• Rittenour WR, Chen M, Cahoon EB, et al. Control of glucosylceramide production and morphogenesis by the Bar1 ceramide synthase in Fusarium graminearum. PLoS One. 2011;6(4):e19385.
   PubMed Web of Science ®Google Scholar
• Munshi MA, Gardin JM, Singh A, et al. The role of ceramide synthases in the pathogenicity of Cryptococcus neoformans. Cell Rep. 2018;22(6):1392–1400.
   PubMed Web of Science ®Google Scholar
• Li S, Bao D, Yuen G, et al. basA regulates cell wall organization and asexual/sexual sporulation ratio in Aspergillus nidulans. Genetics. 2007;176(1):243–253.
   PubMed Web of Science ®Google Scholar
• Gault CR, Obeid LM, Hannun YA An overview of sphingolipid metabolism: from synthesis to breakdown. In: Sphingolipids as signaling and regulatory molecules. Springer; 2010. p. 1–23.
   Google Scholar
• Cheng J, Park T-S, Chio L-C, et al. Induction of apoptosis by sphingoid long-chain bases in Aspergillus nidulans. Mol Cell Biol. 2003;23(1):163–177.
   PubMed Web of Science ®Google Scholar
• Humpf H-U, Schmelz E-M, Meredith FI, et al. Acylation of naturally occurring and synthetic 1-deoxysphinganines by ceramide synthase formation of N-palmitoyl-aminopentol produces a toxic metabolite of hydrolyzed fumonisin, AP1, and a new category of ceramide synthase inhibitor. J Biol Chem. 1998;273(30):19060–19064.
   PubMed Web of Science ®Google Scholar
• Delgado A, Casas J, Llebaria A, et al. Inhibitors of sphingolipid metabolism enzymes. Biochimi Biophys Acta (BBA) Biomembr. 2006;1758(12):1957–1977.
   PubMed Web of Science ®Google Scholar
• Mandala SM, Thornton RA, Frommer BR, et al. The discovery of australifungin, a novel inhibitor of sphinganine N-acyltransferase from Sporormiella australis. J Antibiot (Tokyo). 1995;48(5):349–356.
   PubMed Web of Science ®Google Scholar
• Harrison LR, Colvin BM, Greene JT, et al. Pulmonary edema and hydrothorax in swine produced by fumonisin B1, a toxic metabolite of Fusarium moniliforme. J Vet Diagn Invest. 1990;2(3):217–221.
   PubMedGoogle Scholar
• Voss KA, Riley RT, Norred W, et al. An overview of rodent toxicities: liver and kidney effects of fumonisins and Fusarium moniliforme. Environ Health Perspect. 2001;109(suppl 2):259–266.
   PubMedGoogle Scholar
• Kim HJ, Qiao Q, Toop HD, et al. A fluorescent assay for ceramide synthase activity. J Lipid Res. 2012;53(8):1701–1707.
   PubMed Web of Science ®Google Scholar
• Michel C, van Echten-deckert G, Rother J, et al. Characterization of ceramide synthesis a dihydroceramide desaturase introduces the 4, 5-trans-double bond of sphingosine at the level of dihydroceramide. J Biol Chem. 1997;272(36):22432–22437.
   PubMed Web of Science ®Google Scholar
• Ternes P, Franke S, Zähringer U, et al. Identification and characterization of a sphingolipid Δ4-desaturase family. J Biol Chem. 2002;277(28):25512–25518.
   PubMed Web of Science ®Google Scholar
• Fernandes C, De Castro P, Singh A, et al. Functional characterization of the A spergillus nidulans glucosylceramide pathway reveals that LCB Δ8‐desaturation and C9‐methylation are relevant to filamentous growth, lipid raft localization and Psd1 defensin activity. Mol Microbiol. 2016;102(3):488–505.
   PubMed Web of Science ®Google Scholar
• Oura T, Kajiwara S. Disruption of the sphingolipid Δ8-desaturase gene causes a delay in morphological changes in Candida albicans. Microbiology. 2008;154(12):3795–3803.
   PubMedGoogle Scholar
• Noble SM, French S, Kohn LA, et al. Systematic screens of a Candida albicans homozygous deletion library decouple morphogenetic switching and pathogenicity. Nat Genet. 2010;42(7):590.
   PubMed Web of Science ®Google Scholar
• Singh A, Wang H, Silva LC, et al. Methylation of glycosylated sphingolipid modulates membrane lipid topography and pathogenicity of Cryptococcus neoformans. Cell Microbiol. 2012;14(4):500–516.
   PubMed Web of Science ®Google Scholar
• Del Poeta M, Nimrichter L, Rodrigues ML, et al. Synthesis and biological properties of fungal glucosylceramide. PLoS Pathog. 2014;10(1):e1003832.
   PubMed Web of Science ®Google Scholar
• Halter D, Neumann S, van Dijk SM, et al. Pre-and post-Golgi translocation of glucosylceramide in glycosphingolipid synthesis. J Cell Biol. 2007;179(1):101–115.
   PubMed Web of Science ®Google Scholar
• Rittershaus PC, Kechichian TB, Allegood JC, et al. Glucosylceramide synthase is an essential regulator of pathogenicity of Cryptococcus neoformans. J Clin Invest. 2006;116(6):1651–1659.
   PubMed Web of Science ®Google Scholar
• Oura T, Kajiwara S. Candida albicans sphingolipid C9-methyltransferase is involved in hyphal elongation. Microbiology. 2010;156(4):1234–1243.
   PubMedGoogle Scholar
• Levery SB, Momany M, Lindsey R, et al. Disruption of the glucosylceramide biosynthetic pathway in Aspergillus nidulans and Aspergillus fumigatus by inhibitors of UDP‐Glc: ceramide glucosyltransferase strongly affects spore germination, cell cycle, and hyphal growth. FEBS Lett. 2002;525(1–3):59–64.
   PubMed Web of Science ®Google Scholar
• Mor V, Rella A, Farnoud AM, et al. Identification of a new class of antifungals targeting the synthesis of fungal sphingolipids. MBio. 2015;6(3):e00647–15.
   PubMed Web of Science ®Google Scholar
• Lazzarini C, Haranahalli K, Rieger R, et al. Acylhydrazones as antifungal agents targeting the synthesis of fungal sphingolipids. Antimicrob Agents Chemother. 2018;62(5):e00156–18.
   PubMed Web of Science ®Google Scholar
• Haranahalli K, Lazzarini C, Sun Y, et al. SAR studies on aromatic acylhydrazone-based inhibitors of fungal sphingolipid synthesis as next-generation antifungal agents. J Med Chem. 2019;62(17):8249–8273.
   PubMed Web of Science ®Google Scholar
• Rodrigues ML, Shi L, Barreto-Bergter E, et al. Monoclonal antibody to fungal glucosylceramide protects mice against lethal Cryptococcus neoformans infection. Clin Vaccine Immunol. 2007;14(10):1372–1376.
   PubMedGoogle Scholar
• Mor V, Farnoud AM, Singh A, et al. Glucosylceramide administration as a vaccination strategy in mouse models of cryptococcosis. PloS One. 2016;11(4):e0153853.
   Web of Science ®Google Scholar
• Heidler SA, Radding JA. Inositol phosphoryl transferases from human pathogenic fungi. Biochim Biophys Acta Mol Basis Dis. 2000;1500(1):147–152.
   Web of Science ®Google Scholar
• Heidler SA, Radding JA. The AUR1 gene in Saccharomyces cerevisiae encodes dominant resistance to the antifungal agent aureobasidin A (LY295337). Antimicrob Agents Chemother. 1995;39(12):2765–2769.
   PubMed Web of Science ®Google Scholar
• Hashida-Okado T, Ogawa A, Endo M, et al. AUR1, a novel gene conferring aureobasidin resistance onSaccharomyces cerevisiae: a study of defective morphologies in Aur1p-depleted cells. Mol Gen Genet. 1996;251(2):236–244.
   PubMedGoogle Scholar
• Luberto C, Toffaletti DL, Wills EA, et al. Roles for inositol-phosphoryl ceramide synthase 1 (IPC1) in pathogenesis of C. neoformans. Genes Dev. 2001;15(2):201–212.
   PubMed Web of Science ®Google Scholar
• TAKESAKO K, KURODA H, INOUE T, et al. Biological properties of aureobasidin A, a cyclic depsipeptide antifungal antibiotic. J Antibiot (Tokyo). 1993;46(9):1414–1420.
   PubMed Web of Science ®Google Scholar
• Nagiec MM, Nagiec EE, Baltisberger JA, et al. Sphingolipid synthesis as a target for antifungal drugs complementation of the inositol phosphorylceramide synthase defect in a mutant strain of Saccharomyces cerevisiae by the AUR1 gene. J Biol Chem. 1997;272(15):9809–9817.
   PubMed Web of Science ®Google Scholar
• Georgopapadakou NH. Antifungals targeted to sphingolipid synthesis: focus on inositol phosphorylceramide synthase. Expert Opin Investig Drugs. 2000;9(8):1787–1796.
   PubMed Web of Science ®Google Scholar
• Sugimoto Y, Sakoh H, Yamada K. IPC synthase as a useful target for antifungal drugs. Curr Drug Targets. 2004;4(4):311–322.
   Google Scholar
• Harris GH, Shafiee A, Cabello MA, et al. Inhibition of fungal sphingolipid biosynthesis by rustmicin, galbonolide B and their new 21-hydroxy analogs. J Antibiot (Tokyo). 1998;51(9):837–844.
   PubMed Web of Science ®Google Scholar
• Mandala SM, Thornton RA, Rosenbach M, et al. Khafrefungin, a novel inhibitor of sphingolipid synthesis. J Biol Chem. 1997;272(51):32709–32714.
   PubMed Web of Science ®Google Scholar
• Jenkins GM, Richards A, Wahl T, et al. Involvement of yeast sphingolipids in the heat stress response of Saccharomyces cerevisiae. J Biol Chem. 1997;272(51):32566–32572.
   PubMed Web of Science ®Google Scholar
• Chung N, Jenkins G, Hannun YA, et al. Sphingolipids signal heat stress-induced ubiquitin-dependent proteolysis. J Biol Chem. 2000;275(23):17229–17232.
   PubMed Web of Science ®Google Scholar
• Rosenberg A, Ene IV, Bibi M, et al. Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia. Nat Commun. 2018;9(1):1–14.
   PubMedGoogle Scholar
• Mandala SM, Thornton RA, Milligan J, et al. Rustmicin, a potent antifungal agent, inhibits sphingolipid synthesis at inositol phosphoceramide synthase. J Biol Chem. 1998;273(24):14942–14949.
   PubMed Web of Science ®Google Scholar
• Mille C, Janbon G, Delplace F, et al. Inactivation of CaMIT1 inhibits Candida albicans phospholipomannan β-mannosylation, reduces virulence, and alters cell wall protein β-mannosylation. J Biol Chem. 2004;279(46):47952–47960.
   PubMed Web of Science ®Google Scholar
• Kotz A, Wagener J, Engel J, et al. The mitA gene of Aspergillus fumigatus is required for mannosylation of inositol-phosphorylceramide, but is dispensable for pathogenicity. Fungal Genet Biol. 2010;47(2):169–178.
   PubMed Web of Science ®Google Scholar
• Prasad T, Saini P, Gaur NA, et al. Functional analysis of CaIPT1, a sphingolipid biosynthetic gene involved in multidrug resistance and morphogenesis of Candida albicans. Antimicrob Agents Chemother. 2005;49(8):3442–3452.
   PubMed Web of Science ®Google Scholar
• Gao J, Wang H, Li Z, et al. Candida albicans gains azole resistance by altering sphingolipid composition. Nat Commun. 2018;9(1):1–14.
   PubMedGoogle Scholar
• Bossche HV, Koymans L, Moereels H. P450 inhibitors of use in medical treatment: focus on mechanisms of action. Pharmacol Ther. 1995;67(1):79–100.
   PubMed Web of Science ®Google Scholar
• Singh A, MacKenzie A, Girnun G, et al. Analysis of sphingolipids, sterols, and phospholipids in human pathogenic Cryptococcus strains. J Lipid Res. 2017;58(10):2017–2036.
   Web of Science ®Google Scholar
• Fabri JHTM, Godoy NL, Rocha MC, et al. The AGC kinase YpkA regulates sphingolipids biosynthesis and physically interacts with SakA MAP kinase in Aspergillus fumigatus. Front Microbiol. 2019;9:3347.
   PubMed Web of Science ®Google Scholar
• Lattif AA, Mukherjee PK, Chandra J, et al. Lipidomics of Candida albicans biofilms reveals phase-dependent production of phospholipid molecular classes and role for lipid rafts in biofilm formation. Microbiology. 2011;157(Pt 11):3232.
   PubMedGoogle Scholar
• Prasad R, Singh A. Lipids of Candida albicans and their role in multidrug resistance. Curr Genet. 2013;59(4):243–250.
   PubMed Web of Science ®Google Scholar
• Ejsing CS, Sampaio JL, Surendranath V, et al. Global analysis of the yeast lipidome by quantitative shotgun mass spectrometry. Proc Nat Acad Sci. 2009;106(7):2136–2141.
   PubMed Web of Science ®Google Scholar
• Cowen LE, Sanglard D, Howard SJ, et al. Mechanisms of antifungal drug resistance. Cold Spring Harb Perspect Med. 2015;5(7):a019752.
   Web of Science ®Google Scholar
• Ami RB, Lewis R, Kontoyiannis DP. Immunopharmacology of modern antifungals. Clinl Infect Dis. 2008;47(2):226–235.
   PubMed Web of Science ®Google Scholar
• Fernandes CM, Goldman GH, Del Poeta M. Biological roles played by sphingolipids in dimorphic and filamentous fungi. MBio. 2018;9(3):e00642–18.
   PubMed Web of Science ®Google Scholar
• Rollin-Pinheiro R, Singh A, Barreto-Bergter E, et al. Sphingolipids as targets for treatment of fungal infections. Future Med Chem. 2016;8(12):1469–1484.
   PubMed Web of Science ®Google Scholar